Sensyne's 'MagnifEye' gets MHRA special use authorisation.

Clinical artificial intelligence (AI) company Sensyne Health announced on Friday that its ‘MagnifEye’ software application, which uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted special use authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA).

Sensyne Health
07 May 2021 08:55:51

Source: Sharecast

The AIM-traded firm said the authorisation was specifically for the use of MagnifEye with the Innova Covid-19 lateral flow self-test kit, which was the platform originally used to test the MagnifEye technology as part of the NHS Digital pilot study.

It said the Innova lateral flow test was used as it was currently the only test to have received temporary MHRA derogation, and would continue to be used with MagnifEye under the authorisation of special use.

The company said it was also pursuing a wider authorisation for the use of MagnifEye with other manufacturers' kits and for other medical indications, and was working with its exclusive licence and technology partner Excalibur Healthcare Services.

“MagnifEye has demonstrated that it has the potential to play an important role in Covid-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation,” said chief executive officer Lord Drayson.

“We believe our technology also demonstrates the value of AI in the analysis of medical images, a field that Sensyne has deep expertise in.”

At 0827 BST, shares in Sensyne Health were up 2.02% at 166.8p.

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.